We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
-$440K
Cap. Flow
-$163M
Cap. Flow %
-11.2%
Top 10 Hldgs %
60.09%
Holding
84
New
10
Increased
23
Reduced
32
Closed
17

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$24.1M
2
ZIMV
ZimVie
ZIMV
+$23.4M
3
FTRE icon
Fortrea Holdings
FTRE
+$10.8M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$10.2M
5
BHC icon
Bausch Health
BHC
+$10.1M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$44.6M
2
UTHR icon
United Therapeutics
UTHR
+$35.3M
3
NTRA icon
Natera
NTRA
+$34.8M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$26M
5
NVO
Novo Nordisk
NVO
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 89.3%
2 Miscellaneous 10.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBIO
51
Zenas BioPharma
ZBIO
$2.04B
$3.22M 0.22%
+190,531
New +$3.43M
MREO
52
Mereo BioPharma
MREO
$40.3M
$3.2M 0.22%
777,890
+281,719
+57% +$1.17M
IQV icon
53
IQVIA
IQV
$43.1B
$3.11M 0.21%
13,138
+960
+8% +$227K
MRVI icon
54
Maravai LifeSciences
MRVI
$1.14B
$2.8M 0.19%
+336,966
New +$2.91M
XOMA
55
DELISTED
Xoma
XOMA
$2.5M 0.17%
94,289
+2,382
+3% +$64.5K
IFRX icon
56
InflaRx
IFRX
$329M
$2.48M 0.17%
1,621,787
+54,857
+4% +$83.5K
TRML
57
DELISTED
Tourmaline Bio
TRML
$2.17M 0.15%
84,380
-120,401
-59% -$2.01M
AMRN
58
Amarin Corp
AMRN
$295M
$2.07M 0.14%
165,465
-49,961
-23% -$663K
NVRO
59
DELISTED
NEVRO CORP.
NVRO
$1.75M 0.12%
313,780
-185,615
-37% -$1.3M
ALEC icon
60
Alector
ALEC
$261M
$1.55M 0.11%
332,756
-208,983
-39% -$1.12M
AUTL
61
Autolus Therapeutics
AUTL
$623M
$1.48M 0.1%
406,558
-204,344
-33% -$815K
LQDA icon
62
Liquidia Corp
LQDA
$6.06B
$1.38M 0.09%
137,949
-235,605
-63% -$2.57M
ABSI icon
63
Absci
ABSI
$1.49B
$1.04M 0.07%
272,869
-52,640
-16% -$209K
JBIO
64
Jade Biosciences
JBIO
$1.33B
$1.01M 0.07%
+13,861
New +$894K
STOK icon
65
Stoke Therapeutics
STOK
$2.04B
$639K 0.04%
52,006
-9,271
-15% -$131K
AFMD
66
DELISTED
Affimed
AFMD
$559K 0.04%
166,460
– –
ACIU icon
67
AC Immune
ACIU
$263M
$375K 0.03%
99,313
– –
ARGX icon
68
argenx
ARGX
$64B
– –
-34,593
Closed -$14.9M
CYTK icon
69
Cytokinetics
CYTK
$10B
– –
-126,877
Closed -$6.87M
FULC icon
70
Fulcrum Therapeutics
FULC
$294M
– –
-152,965
Closed -$948K
GH icon
71
Guardant Health
GH
$21.7B
– –
-99,377
Closed -$2.87M
IMVT icon
72
Immunovant
IMVT
$8.51B
– –
-92,909
Closed -$2.45M
LLY icon
73
Eli Lilly
LLY
$1.05T
– –
-21,233
Closed -$19.2M
MCRB icon
74
Seres Therapeutics
MCRB
$51.3M
– –
-20,910
Closed -$303K
MLTX icon
75
MoonLake Immunotherapeutics
MLTX
$1.28B
– –
-71,596
Closed -$3.15M
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Eversept Partners held 84 positions worth $1.46B, down 0.03% from $1.46B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners withdrew a net $163M in Q3 2024, closing 17 positions and reducing 32 holdings. Its most notable exit was Novo Nordisk, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

Against the trend, Eversept Partners opened a new position in Fortrea Holdings worth $9.16M.

  • Eversept Partners's largest Q3 2024 buy was Fortrea Holdings: 457,967 shares worth $9.16M.
  • Eversept Partners added most to GSK in Q3 2024, an estimated $24.1M increase.
  • Eversept Partners's biggest Q3 2024 reduction was Inspire Medical Systems, cutting an estimated $44.6M.
  • Eversept Partners fully exited Novo Nordisk in Q3 2024, selling an estimated $21M.
  • Eversept Partners's ten largest holdings make up 60% of its $1.46B portfolio in Q3 2024.
  • Eversept Partners opened 10 new positions and closed 17 in Q3 2024.
  • Eversept Partners's portfolio value fell 0.03% quarter-over-quarter to $1.46B.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.